Table 4.
Efficacy of first-line therapy
| All patients % (N) |
Triplet (N = 12) % (N) |
No triplet % (N) |
moABX (N = 31) % (N) |
No moABX (N = 20) % (N) |
|
|---|---|---|---|---|---|
| ORR (N = 39) | 33.3 (13) | 72.7% (8) | 17.9% (5) | 42.3% (11) | 15.4% (2) |
| Odds ratio (95% CI) |
OR = 12.267 (2.375–63.360) p* = 0.002 |
OR = 4.033 (0.740–21.983) p* = 0.151 | |||
| DCR | 59.0 (23) | 81.8% (9) | 50% (14) | 73.1% (19) | 30.8% (4) |
| Odds ratio (95% CI) |
OR = 4.500 (0.821–24.679) p* = 0.086 |
OR = 6.107 (1.415–26.356) p* = 0.017 |
|||
| Median PFS (months) (N = 43) (95% CI) | 8.4 (3.8–13.0) | 13.0 (12.9–13.1) | 4.3 (2.3–6.3) | 10.5 (8.0–13.1) | 3.1 (1.5–4.8) |
| Hazard ratio (95% CI) |
p# = 0.018 HR = 0.325 (0.121–0.873); p = 0.026 |
p# = 0.063 HR = 0.474 (0.210–1.068); p = 0.072 |
|||
| Median OS (months) (N = 51) (95% CI) | 17.6 (12.6–22.7) | 22.1 (14.7–29.4) | 15.0 (9.9–20.1) | 24.8 (19.3–30.3) | 9.7 (3.4–16.0) |
| Hazard ratio (95% CI) |
p# = 0.404 HR = 0.730 (0.347–1.534); p = 0.406 |
p# = 0.040 HR = 0.523 (0.279–0.981); p = 0.043 |
|||
*Two sided Fisher’s exact test; OR = odds ratio
#Log rank test; HR: hazard ratio